289 related articles for article (PubMed ID: 25900065)
61. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Zoellner AK; Höhler T; Fries S; Böhme A; Kiewe P; Kellermann L; Dreyling M
Ann Hematol; 2016 May; 95(6):853-61. PubMed ID: 27021305
[TBL] [Abstract][Full Text] [Related]
62. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
Dearden CE; Richards S; Else M; Catovsky D; Hillmen P
Cancer; 2011 Jun; 117(11):2452-60. PubMed ID: 24048793
[TBL] [Abstract][Full Text] [Related]
63. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
64. Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.
Lew TE; Cheah CY; Carney DA; Prince HM; Wolf M; Bazargan A; Januszewicz EH; Filshie R; Westerman D; Seymour JF; Tam CS
Leuk Lymphoma; 2016 May; 57(5):1044-53. PubMed ID: 26464106
[TBL] [Abstract][Full Text] [Related]
65. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
Kowal M; Dmoszyńska A; Lewandowski K; Hellmann A; Wegrzyn J; Skotnicki AB; Wołowiec D; Kuliczkowski K; Piszcz J; Kłoczko J; Roznowski K; Komarnicki M
Leuk Lymphoma; 2004 Jun; 45(6):1159-65. PubMed ID: 15359995
[TBL] [Abstract][Full Text] [Related]
67. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
[TBL] [Abstract][Full Text] [Related]
68. Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Feugier P; Aurran T; Mahé B; Letestu R; Nguyen-Khac F; Cazin B; Tournilhac O; Maisonneuve H; Casasnovas O; Delmer A; Leblond V; Royer B; Corront B; Chevret S; Delépine R; Vaudaux S; Van Den Neste E; Béné MC; Cymbalista F; Ross-Weil D; Leprêtre S
Haematologica; 2018 Jul; 103(7):e304-e306. PubMed ID: 29545348
[No Abstract] [Full Text] [Related]
69. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
70. Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
Kreiniz N; Garty-Ofir M; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2021 Feb; 39(1):129-133. PubMed ID: 33038272
[TBL] [Abstract][Full Text] [Related]
71. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Johnson GG; Lin K; Cox TF; Oates M; Sibson DR; Eccles R; Lloyd B; Gardiner LJ; Carr DF; Pirmohamed M; Strefford JC; Oscier DG; Gonzalez de Castro D; Else M; Catovsky D; Pettitt AR
Blood; 2013 Dec; 122(26):4253-8. PubMed ID: 24128861
[TBL] [Abstract][Full Text] [Related]
72. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M
Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021
[No Abstract] [Full Text] [Related]
73. Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.
Arampatzis S; Giannakoulas N; Liakopoulos V; Eleftheriadis T; Kourti P; Karasavvidou F; Matsouka P; Stefanidis I
BMC Nephrol; 2011 Jul; 12():33. PubMed ID: 21729272
[TBL] [Abstract][Full Text] [Related]
74. Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia.
Gibiansky E; Gibiansky L; Chavanne C; Frey N; Jamois C
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):914-927. PubMed ID: 34110098
[TBL] [Abstract][Full Text] [Related]
75. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Kater AP; van Oers MHJ; van Norden Y; van der Straten L; Driessen J; Posthuma WFM; Schipperus M; Chamuleau MED; Nijland M; Doorduijn JK; Van Gelder M; Hoogendoorn M; De Croon F; Wittebol S; Kerst JM; Marijt EWA; Raymakers RAP; Schaafsma MR; Dobber JA; Kersting S; Levin MD;
Haematologica; 2019 Jan; 104(1):147-154. PubMed ID: 30115656
[TBL] [Abstract][Full Text] [Related]
76. Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Cartron G; Letestu R; Dartigeas C; Tout M; Mahé B; Gagez AL; Ferrant E; Guiu B; Villemagne B; Letuan P; Aurran T; Orsini-Piocelle F; Banos A; Feugier P; Leblond V; de Guibert S; Tournilhac O; Dupuis J; Delmer A; Rouillé V; Ternant D; Leprêtre S
Haematologica; 2018 Aug; 103(8):e356-e359. PubMed ID: 29519866
[No Abstract] [Full Text] [Related]
77. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
[TBL] [Abstract][Full Text] [Related]
78. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
[No Abstract] [Full Text] [Related]
79. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
Kutsch N; Busch R; Bahlo J; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Wendtner CM; Maria Fink A; Fischer K; Hallek M; Eichhorst B
Leuk Lymphoma; 2017 Feb; 58(2):399-407. PubMed ID: 27357445
[TBL] [Abstract][Full Text] [Related]
80. COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Allsup D; Howard D; Emmerson J; Hockaday A; Rawstron A; Oughton JB; Bloor A; Phillips D; Nathwani A; Paneesha S; Turner D; Munir T; Hillmen P
Br J Haematol; 2021 Aug; 194(3):646-650. PubMed ID: 34028800
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
